Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Available alternatives: Is there already an FDA-approved drug that makes compounding unnecessary
Cell (2017) This landmark Cell publication from Erasmus University Medical Center introduced FOXO4-DRI as a senolytic peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 interaction
Importantly, responses need to reflect reality: people are already using these substances
Its peptide arm is built on established US makers Vivitide and Pepscan, backed by a broad catalog of biochemical reagents and full analytical support
Hinyokika Kiyo
The syringe size does not affect the peptide
US$ 28.97
US$ 24.83
US$ 29.97
US$ 22.54
US$ 21.94
US$ 23.32
US$ 29.09
